Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression
暂无分享,去创建一个
Stephen M. Hewitt | Catherine M. Conway | Carlos Caldas | Douglas F. Easton | Stephen J. Chanock | Jolanta Lissowska | Montserrat Garcia-Closas | Fiona M. Blows | Mark E. Sherman | Jonine D. Figueroa | Sarah-Jane Dawson | S. Chanock | M. García-Closas | D. Easton | C. Caldas | S. Dawson | P. Pharoah | L. Prokunina-Olsson | M. Sherman | L. Brinton | J. Lissowska | J. Figueroa | S. Hewitt | F. Blows | Xiaohong R. Yang | Ludmila Prokunina-Olsson | Louise A. Brinton | Paul D. Pharoah | C. Conway | Hisani N. Horne
[1] B. Győrffy,et al. Identification of a claudin‐4 and E‐cadherin score to predict prognosis in breast cancer , 2011, Cancer science.
[2] Patrick Neven,et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. , 2011, Human molecular genetics.
[3] M. Colleoni,et al. Adjuvant therapies for special types of breast cancer. , 2011, Breast.
[4] Jaana M. Hartikainen,et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk , 2013, Nature Genetics.
[5] C. Caldas,et al. Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance , 2011, Breast Cancer Research.
[6] Michael Jones,et al. Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. , 2011, Human molecular genetics.
[7] Peter Kraft,et al. Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status , 2012, Journal of Medical Genetics.
[8] W. Birchmeier,et al. Role of morphogenetic factors in metastasis of mammary carcinoma cells , 1998, Oncogene.
[9] M. García-Closas,et al. Established breast cancer risk factors by clinically important tumour characteristics , 2006, British Journal of Cancer.
[10] C. Shapiro,et al. Stem cell-related markers in primary breast cancers and associated metastatic lesions , 2012, Modern Pathology.
[11] M. García-Closas,et al. Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. , 2007, Cancer research.
[12] S. Shousha,et al. Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study. , 1998, Journal of clinical pathology.
[13] Montserrat Garcia-Closas,et al. Genetic susceptibility to breast cancer , 2010, Molecular oncology.
[14] Gerhard Christofori,et al. A causal role for E-cadherin in the transition from adenoma to carcinoma , 1998, Nature.
[15] A. Børresen-Dale,et al. NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations , 2010, Molecular Cancer.
[16] Manolis Kellis,et al. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants , 2011, Nucleic Acids Res..
[17] S. Pinder,et al. E‐cadherin expression in invasive non‐lobular carcinoma of the breast and its prognostic significance , 2005, Histopathology.
[18] M. García-Closas,et al. Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study , 2007, Cancer Epidemiology Biomarkers & Prevention.
[19] F. Vicini,et al. Clinicopathologic implications of E‐cadherin reactivity in patients with lobular carcinoma in situ of the breast , 2001, Cancer.
[20] Patrick Neven,et al. Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) , 2012, PloS one.
[21] Carlos Caldas,et al. Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer , 2009, International journal of cancer.
[22] T. Rebbeck,et al. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. , 2001, American journal of clinical pathology.
[23] J. Visvader,et al. Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. , 2008, Cell stem cell.
[24] W. Willett,et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1) , 2009, Nature Genetics.
[25] Lester L. Peters,et al. Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.
[26] Peter Kraft,et al. A Genome-Wide Association Study of Prognosis in Breast Cancer , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[27] Frank McCormick,et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. , 2004, Genes & development.
[28] Wei Zheng,et al. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. , 2011, The Lancet. Oncology.